Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146530 | 0.83 | GPR84 (0.57) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL29473770 | 0.83 | GPR84 (0.57) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL19686032 | 0.80 | MAOB (0.40) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL14221267 | 0.80 | P2RX4 (0.46) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL7299293 | 0.78 | KDM4E (0.53) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL1421538 | 0.78 | ALDH1A1 (0.50) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL2747859 | 0.78 | HTT (0.53) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL11401880 | 0.78 | L3MBTL1 (0.48) | ALDH1A1IMPDH2KDM4EGPR84CCNE2 | |
| SCHEMBL19685965 | 0.78 | MAOB (0.39) | ALDH1A1IMPDH2KDM4ECCNE2CDK4 | |
| SCHEMBL436410 | 0.77 | TP53 (0.49) | ALDH1A1IMPDH2KDM4EMAOBGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0330340-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1989-08-30 | — | — | EP | claimed |
| WO-1989007593-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1989-08-24 | — | — | WO | claimed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| EP-2821401-B1 | DIHYDROQUINOLINONE COMPOUNDS AS MODULATORS OF THE MUSCARININC M1 RECEPTOR | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-09 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-16 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| US-20090143368-A1 | Use of Cinnamoyl Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1857455-A1 | CINNAMOYL COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-0330340-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989007593-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1989-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ALDH1A1 144/4885IMPDH2 759/4885KDM4E 1301/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | ALDH1A1 89/4885IMPDH2 1395/4885KDM4E 821/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ALDH1A1 144/4885IMPDH2 759/4885KDM4E 1301/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | ALDH1A1 1614/4885IMPDH2 2625/4885KDM4E 2537/4885 |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | COL2A1, MMP7, COL14A1 | ALDH1A1 474/4885IMPDH2 3056/4885KDM4E 2703/4885 |
| US-20140309220-A1 | BENZOXAZINES AS MODULATORS OF ION CHANNELS | KCNJ1, KCNJ2, KCNJ11 | ALDH1A1 1441/4885IMPDH2 3022/4885KDM4E 1795/4885 |
| US-20090143368-A1 | Use of Cinnamoyl Compound | COL2A1, COL1A1, SMAD2 | ALDH1A1 749/4885IMPDH2 3779/4885KDM4E 1537/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | ALDH1A1 461/4885IMPDH2 3246/4885KDM4E 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.